TNXB

Across TCGA pan-cancer cohorts, TNXB Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated TNXB data layer compared with 22 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher TNXB Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TNXB expression acts as an unfavorable survival marker, although some lineages such as SCLC show a favorable association.

LUSC, ACC, and PAAD are the cancer types where TNXB Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	III,IV	0.128	0.690	.001	18	view →
ACC	OS	Median	II,III,IV	0.245	0.775	<.001	13	view →
PAAD	OS	Median	All	0.112	0.640	.004	12	view →
LUAD	OS	Median	III,IV	0.057	0.680	<.001	6	view →
ESCA	OS	Median	II,III,IV	0.248	0.549	.025	3	view →
HNSC	DFS	Median	IV	0.428	0.672	.029	3	view →
BRCA	OS	Median	III,IV	0.507	0.909	.036	2	view →
SCLC	DFS	Median	II,III,IV	0.708	0.289	.039	1	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

TNXB–LUSC (OS)

Open the LUSC breakdown →